Coronavirus Epidemic Has Implications for Life Expectancy

Credit: China.orgBy James LiangBEIJING, China, Feb 17 2020 (IPS) As efforts to contain the Coronavirus epidemic enter a critical stage, it is important to remember that the costs cannot be measured purely in economic terms, as the measures taken will have implications for life expectancy across the entire nation. Analysis of historical data from various countries gives insight into the relationship between life expectancy and GDP per capita. In the first place, it is clear that countries with higher per capita incomes have longer life expectancies, owing to the ability and willingness of wealthier nations to invest in healthcare, infrastructure, and environmental governance, thereby increasing life expectancy and reducing fatality rates. Research suggests that, in general, a 100% increase in per capita income under similar conditions equates to an increase in life expectancy of 1-3 years. Over the past few decades, with the continued increase in per capita income in China, life expectancy has steadily increased in tandem. On the basis of this, we can make a conservative estimate that a 50% decrease in GDP would see a 1.5 year decrease in life expectancy. Thus, for each 1% reduction in in GDP, life expectancy will decrease by approximately 10 days. This hypothesis can be tested against the economic theory of the “value of life”. In the realm of economics, “value of life” is a relatively mature concept which refers to the amount that a society is wil...
Source: IPS Inter Press Service - Health - Category: International Medicine & Public Health Authors: Tags: Asia-Pacific Featured Global Headlines Health IPS UN: Inside the Glasshouse Regional Categories TerraViva United Nations Source Type: news

Related Links:

Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part BAuthor(s): Yanhua Liu, Yang Li, Shanshan Dong, Lu Han, Ruixin Guo, Yourong Fu, Shenghu Zhang, Jianqiu Chen
Source: Journal of Hazardous Materials - Category: Environmental Health Source Type: research
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part AAuthor(s): Zhongyi Zhang, Wen-Xiong Wang, Nengjian Zheng, Yansheng Cao, Hongwei Xiao, Renguo Zhu, Hui Guan, Huayun Xiao
Source: Journal of Hazardous Materials - Category: Environmental Health Source Type: research
Authors: Musio F Abstract INTRODUCTION: Anemia has and will continue to be a central theme in medicine particularly as clinicians are treating a burgeoning population of complex multi-organ system processes. As a result of multiple randomized controlled trials (RCTs), meta-analyses, and societal recommendations overly restrictive paradigms and under-administration of erythropoiesis stimulating agents (ESAs) have likely been followed by clinicians among all specialties. AREAS COVERED: A review of anemia in the context of chronic kidney disease, hematologic malignancies and cancer is presented with focus on the e...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
Publication date: January 2021Source: Urology Case Reports, Volume 34Author(s): Nina Al-Saadi, Safa Al-Musawi, Yousuf Khan, Daben Dawam
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
Authors: Matti B, Zargar-Shoshtari K Abstract Prostate cancer represents a significant health burden worldwide. The cancer incidence had substantially increased since the introduction of prostate specific antigen (PSA) in cancer screening. This had led to considerable debates among health professionals and epidemiologists, since PSA as a screening tool seemed to be far from perfect. In New Zealand, the controversy was quite prominent in the last three decades, with some advocating the benefits of screening, while others concerned regarding the risk of harms. With the absence of an organised screening programme and ...
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research
CONCLUSION: This study found that childhood cancer survivors in New Zealand had a high prevalence of developmental dental abnormalities and it identified potential risk factors related to their cancer treatment. Inequitable access to oral rehabilitation for this patient group argues for a mechanism for consistent improved access to publicly funded dental care across district health boards in New Zealand. PMID: 33032302 [PubMed - in process]
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research
NEW YORK, September 8, 2020 — The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson &Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and Canada, Moderna, Inc. (Nasdaq: MRNA), Novavax, Inc. (Nasdaq: NVAX), Pfizer Inc. (NYSE: PFE), and Sanofi (NASDAQ: SNY), today announced a historic pledge, outlining a united commitment to uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first COVID-19 vaccines. All nine CEOs signed the following pledge: We, the und...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
This article originally appeared on The Bulwark here. The post The False Choice Between Science And Economics appeared first on The Health Care Blog.
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: COVID-19 Health Policy David Shaywitz Source Type: blogs
The worldwide epidemic of three coronaviruses and one influenza virus in 21st century have seriously threatened human health. Infection with these viruses can cause respiratory symptoms. The patients with lung cancer are more susceptible to viral infection and have a worse prognosis due to the advanced age and the systemic immunosuppressive state caused by malignancy itself and the anticancer treatments. In addition, without sufficient clinical awareness, a missed diagnosis of viral pneumonia may occur due to the fever and respiratory symptoms caused by lung cancer and its secondary diseases. Furthermore, control measures ...
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19. It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
More News: Cancer | Cancer & Oncology | Cardiology | Cardiovascular | China Health | Coronavirus | Economics | Economy | Environmental Health | Epidemics | Epidemiology | Government | Heart | History of Medicine | Infectious Diseases | Influenza | International Medicine & Public Health | Jobs | Medical Ethics | Men | Outbreaks | Salaries | Unemployment | United Nations